The issue of medicine-related harm is immense, and how to tackle it is an area of growing interest to governments and healthcare systems alike.
Nitazenes can be up to 50 times stronger than fentanyl. They’re not yet common in Australia, so now’s the time to implement policies to reduce their harm and limit their uptake.
Researchers have completed Australia’s most detailed analysis of opioid tapering trajectories to date, with some findings that contradict current guidelines.
Changes to the Pharmaceutical Benefits Scheme have influenced the way doctors prescribe opioids, but is it for the better?
Loneliness must be regarded as a public health priority. Find out some of the surprising ways we can tackle it in Monash University’s podcast, ‘What Happens Next?’.
The hidden costs of loneliness can devastate both individuals and society. Learn about its modern roots in a new episode of Monash University's podcast, 'What Happens Next?'.
A new, long-acting formulation of the medication buprenorphine promises to improve the treatment of opioid dependence.
There's growing evidence that an escape from underlying physical or emotional pain is a common driver of many opioid overdoses.
We need to look at the issue from a patient perspective. What can we be doing to support patients and safely manage their pain with opioids post-surgery.
New rules aim to curb opioid-related deaths in Australia. These changes are a step in the right direction, but we need to tread carefully to avoid unintended consequences.
Maintaining or expanding addiction services is vital if we’re to avert a syndemic of opioid overdoses and COVID-19.
Treatments for opioid dependence, such as methadone and buprenorphine, are effective. But some people who stand to benefit are missing out.
Opioids are among the most powerful analgesics available to medicine, but they have huge capacity to cause harm. In trying to solve one problem, is a bigger one being created?
Dummy text
